|
MYCN |
MYCN proto-oncogene, bHLH transcription factor |
|
|
- Neuroblastoma
- Feingold syndrome
|
|
NFYB |
nuclear transcription factor Y subunit beta |
- PPARA activates gene expression
- Activation of gene expression by SREBF (SREBP)
- Activation of gene expression by SREBF (SREBP)
- ATF4 activates genes in response to endoplasmic reticulum stress
- ATF6 (ATF6-alpha) activates chaperone genes
- ATF6 (ATF6-alpha) activates chaperone genes
- FOXO-mediated transcription of cell death genes
|
|
|
|
PCBP2 |
poly(rC) binding protein 2 |
- mRNA Splicing - Major Pathway
- Processing of Capped Intron-Containing Pre-mRNA
- Negative regulators of DDX58/IFIH1 signaling
|
|
|
|
PCNA |
proliferating cell nuclear antigen |
- Translesion synthesis by REV1
- Recognition of DNA damage by PCNA-containing replication complex
- Translesion Synthesis by POLH
- Transcription of E2F targets under negative control by DREAM complex
- Polymerase switching on the C-strand of the telomere
- Processive synthesis on the C-strand of the telomere
- Telomere C-strand (Lagging Strand) Synthesis
- Removal of the Flap Intermediate from the C-strand
- SUMOylation of DNA replication proteins
- Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)
- Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)
- PCNA-Dependent Long Patch Base Excision Repair
- Translesion synthesis by POLK
- Translesion synthesis by POLI
- Termination of translesion DNA synthesis
- HDR through Homologous Recombination (HRR)
- Gap-filling DNA repair synthesis and ligation in GG-NER
- Dual Incision in GG-NER
- Dual incision in TC-NER
- Gap-filling DNA repair synthesis and ligation in TC-NER
- TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
- Polymerase switching
- Removal of the Flap Intermediate
- Processive synthesis on the lagging strand
- G1/S-Specific Transcription
- E3 ubiquitin ligases ubiquitinate target proteins
|
- Liothyronine
- Acetylsalicylic acid
|
|
|
PRPF40A |
pre-mRNA processing factor 40 homolog A |
- mRNA Splicing - Major Pathway
|
|
|
|
PURA |
purine rich element binding protein A |
|
|
|
|
RBBP6 |
RB binding protein 6, ubiquitin ligase |
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|
|
RPS6KA1 |
ribosomal protein S6 kinase A1 |
- ERK/MAPK targets
- CREB phosphorylation
- Senescence-Associated Secretory Phenotype (SASP)
- Senescence-Associated Secretory Phenotype (SASP)
- Recycling pathway of L1
- CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling
- RSK activation
- RSK activation
- Gastrin-CREB signalling pathway via PKC and MAPK
|
- Purvalanol A
- Fostamatinib
|
|
|
RPS6KA3 |
ribosomal protein S6 kinase A3 |
- ERK/MAPK targets
- CREB phosphorylation
- Senescence-Associated Secretory Phenotype (SASP)
- Senescence-Associated Secretory Phenotype (SASP)
- Recycling pathway of L1
- CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling
- RSK activation
- RSK activation
- Gastrin-CREB signalling pathway via PKC and MAPK
|
- Acetylsalicylic acid
- Fostamatinib
|
- Non-syndromic X-linked mental retardation
- Coffin-Lowry syndrome (CLS)
|
|
SLC6A4 |
solute carrier family 6 member 4 |
- Serotonin clearance from the synaptic cleft
|
- Fluvoxamine
- Amphetamine
- Phentermine
- Tramadol
- Citalopram
- Benzatropine
- Venlafaxine
- Atomoxetine
- Amitriptyline
- Protriptyline
- Loxapine
- Meperidine
- Imipramine
- Fluoxetine
- Duloxetine
- Dextromethorphan
- Nortriptyline
- Amoxapine
- Fenfluramine
- Mazindol
- Trazodone
- Verapamil
- Paroxetine
- Trimipramine
- Minaprine
- Pseudoephedrine
- Cocaine
- Cyclobenzaprine
- Dopamine
- Sertraline
- Sibutramine
- Chlorpheniramine
- Doxepin
- Nefazodone
- Desipramine
- Escitalopram
- Dexfenfluramine
- Aripiprazole
- Clomipramine
- Ephedra sinica root
- MMDA
- Midomafetamine
- 4-Methoxyamphetamine
- Metamfetamine
- Nomifensine
- Zimelidine
- Amineptine
- Bicifadine
- Milnacipran
- OPC-14523
- CRx-119
- Amitifadine
- Lumateperone
- Mianserin
- Tesofensine
- Tapentadol
- Vilazodone
- Desvenlafaxine
- Dexmethylphenidate
- Serotonin
- Levomilnacipran
- Butriptyline
- Vortioxetine
- Dosulepin
- Nisoxetine
- Lorpiprazole
- Zotepine
- Dasotraline
|
|
|
SMAD3 |
SMAD family member 3 |
- Signaling by NODAL
- Signaling by NODAL
- Signaling by Activin
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling activates SMADs
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- SMAD4 MH2 Domain Mutants in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- TGFBR1 KD Mutants in Cancer
- Ub-specific processing proteases
- RUNX3 regulates CDKN1A transcription
- RUNX3 regulates BCL2L11 (BIM) transcription
- Interleukin-37 signaling
- NOTCH4 Intracellular Domain Regulates Transcription
- FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
- FOXO-mediated transcription of cell cycle genes
- FOXO-mediated transcription of cell cycle genes
|
|
|
|
SMU1 |
SMU1 DNA replication regulator and spliceosomal factor |
|
|
|
|
SREK1 |
splicing regulatory glutamic acid and lysine rich protein 1 |
|
|
|
|
SRSF9 |
serine and arginine rich splicing factor 9 |
- Transport of Mature mRNA derived from an Intron-Containing Transcript
- mRNA Splicing - Major Pathway
- mRNA 3'-end processing
- RNA Polymerase II Transcription Termination
|
|
|
|
TFAP2A |
transcription factor AP-2 alpha |
- Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors
- Negative regulation of activity of TFAP2 (AP-2) family transcription factors
- Negative regulation of activity of TFAP2 (AP-2) family transcription factors
- TFAP2 (AP-2) family regulates transcription of other transcription factors
- Activation of the TFAP2 (AP-2) family of transcription factors
- TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
- TFAP2 (AP-2) family regulates transcription of cell cycle factors
- TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation
|
|
- Branchiooculofacial syndrome (BOFS)
|
|
TP53 |
tumor protein p53 |
- Activation of NOXA and translocation to mitochondria
- Activation of PUMA and translocation to mitochondria
- Pre-NOTCH Transcription and Translation
- Oxidative Stress Induced Senescence
- Formation of Senescence-Associated Heterochromatin Foci (SAHF)
- Oncogene Induced Senescence
- DNA Damage/Telomere Stress Induced Senescence
- SUMOylation of transcription factors
- Autodegradation of the E3 ubiquitin ligase COP1
- Association of TriC/CCT with target proteins during biosynthesis
- TP53 Regulates Metabolic Genes
- Ub-specific processing proteases
- Ovarian tumor domain proteases
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Interleukin-4 and Interleukin-13 signaling
- TP53 Regulates Transcription of DNA Repair Genes
- TP53 Regulates Transcription of Genes Involved in Cytochrome C Release
- TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain
- TP53 Regulates Transcription of Caspase Activators and Caspases
- TP53 Regulates Transcription of Death Receptors and Ligands
- TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
- TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain
- TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
- Regulation of TP53 Expression
- Regulation of TP53 Activity through Phosphorylation
- Regulation of TP53 Degradation
- Regulation of TP53 Activity through Acetylation
- Regulation of TP53 Activity through Association with Co-factors
- Regulation of TP53 Activity through Methylation
- PI5P Regulates TP53 Acetylation
- G2/M DNA damage checkpoint
- G2/M Checkpoints
- Stabilization of p53
- Transcriptional activation of cell cycle inhibitor p21
- The role of GTSE1 in G2/M progression after G2 checkpoint
- Transcriptional Regulation by VENTX
- RUNX3 regulates CDKN1A transcription
- Regulation of PTEN gene transcription
- Regulation of PTEN gene transcription
- Factors involved in megakaryocyte development and platelet production
|
- Acetylsalicylic acid
- Zinc
- Triethyl phosphate
- AZD 3355
- 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine
- Zinc acetate
- Zinc chloride
- Zinc sulfate, unspecified form
|
- Osteosarcoma
- Adrenal carcinoma
- Thyroid cancer
- Breast cancer
- Basal cell carcinoma
- Malignant melanoma
- Pancreatic cancer
- Gastric cancer
- Malignant pleural mesothelioma
- Non-small cell lung cancer
- Esophageal cancer
- Oral cancer
- Multiple myeloma
- Small cell lung cancer
- Li-Fraumeni syndrome, including: Classic Li-Fraumeni syndrome (LFS); LFS-like syndrome (LFSL)
- Glioma
- Squamous cell carcinoma
- Kaposi's sarcoma
- Cholangiocarcinoma
- Gallbladder cancer
- Cancer of the anal canal
- Hepatocellular carcinoma
- Choriocarcinoma
- Vulvar cancer
- Choroid plexus papilloma
- Burkitt lymphoma
- Adult T-cell leukemia
- Hairy-cell leukemia
- Bladder cancer
- Chronic lymphocytic leukemia (CLL)
- Penile cancer
- Endometrial Cancer
- Ovarian cancer
- Colorectal cancer
- Laryngeal cancer
- Chronic myeloid leukemia (CML)
|
|
TRAF6 |
TNF receptor associated factor 6 |
- PIP3 activates AKT signaling
- MyD88:MAL(TIRAP) cascade initiated on plasma membrane
- NOD1/2 Signaling Pathway
- TICAM1, RIP1-mediated IKK complex recruitment
- Regulated proteolysis of p75NTR
- Downstream TCR signaling
- NRIF signals cell death from the nucleus
- NRIF signals cell death from the nucleus
- p75NTR recruits signalling complexes
- NF-kB is activated and signals survival
- FCERI mediated NF-kB activation
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- activated TAK1 mediates p38 MAPK activation
- JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
- CLEC7A (Dectin-1) signaling
- Ub-specific processing proteases
- Ovarian tumor domain proteases
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- TICAM1,TRAF6-dependent induction of TAK1 complex
- Interleukin-1 signaling
- TRAF6 mediated IRF7 activation
- TRAF6 mediated NF-kB activation
- TRAF6 mediated NF-kB activation
- IRAK1 recruits IKK complex
- IKK complex recruitment mediated by RIP1
- IRAK2 mediated activation of TAK1 complex
- TRAF6-mediated induction of TAK1 complex within TLR4 complex
- Alpha-protein kinase 1 signaling pathway
- TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
- MyD88 dependent cascade initiated on endosome
- IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation
- MyD88 cascade initiated on plasma membrane
|
|
|
|
VEGFA |
vascular endothelial growth factor A |
- Platelet degranulation
- Regulation of gene expression by Hypoxia-inducible Factor
- Signaling by VEGF
- VEGF ligand-receptor interactions
- VEGF binds to VEGFR leading to receptor dimerization
- Interleukin-4 and Interleukin-13 signaling
- TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
|
- Bevacizumab
- Minocycline
- Gliclazide
- Carvedilol
- Ranibizumab
- Pidolic acid
- Pegaptanib
- Vandetanib
- ABT-510
- Veglin
- Denibulin
- SNS-032
- Bevasiranib
- Dalteparin
- Aflibercept
- Chondroitin sulfate
- Foreskin keratinocyte (neonatal)
- Brolucizumab
- Faricimab
|
|